People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study.

Crinetics is seeking to change the way acromegaly is treated. Ahead of its hopes for a 2025 U.S. drug launch, the biotech is looking to spread awareness about how to treat the condition.

The AI model correctly diagnosed 22 adults with acromegaly and 24 controls who did not have acromegaly. The model had a sensitivity of 71%, a specificity of 77%, and an area under the receiver ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients. News release. Crinetics Pharmaceuticals.

The randomized, placebo-controlled PATHFNDR-2 study (ClinicalTrials.gov Identifier: NCT05192382) included 111 patients with acromegaly who had elevated IGF-1 levels and were treatment naïve.

Rare Acromegaly Case Reveals Genetic Link and Cardiac Issues Crinetics' Hormonal Disorder Drug Succeeds in Late-stage Study 3090D553-9492-4563-8681-AD288FA52ACE ...